| |
Comment |
 CYP inhbitors
|
|
|
CYP inducers
|
|
|
 CYP substrates
|
CYP1A1 [HSA:1543]
|
CYP1A2 [HSA:1544]
|
Adrenaline - lidocaine
|
Alosetron
|
Sensitive (in vivo) |
Amiodarone [DG:DG00204]
|
Aminophylline
|
Amitriptyline [DG:DG00934]
|
Amoxapine
|
Armodafinil
|
Antipyrine
|
Bortezomib
|
Caffeine
|
Sensitive (in vivo) |
Carvedilol [DG:DG00321]
|
Chlorzoxazone
|
Choline theophyllinate
|
Cimetidine [DG:DG00017]
|
Ciprofloxacin [DG:DG00617]
|
Clomipramine [DG:DG00929]
|
Clopidogrel [DG:DG00155]
|
Clozapine
|
Cyclobenzaprine [DG:DG00775]
|
Dantrolene [DG:DG00778]
|
Dexpropranolol
|
Duloxetine [DG:DG00962]
|
Sensitive (in vivo) |
Eltrombopag
|
Enoxacin [DG:DG00619]
|
Erlotinib [DG:DG00711]
|
Estradiol [DG:DG00462]
|
Fluvoxamine [DG:DG00946]
|
Fosamprenavir [DG:DG00656]
|
Haloperidol [DG:DG00885]
|
Imipramine [DG:DG00928]
|
Levobupivacaine
|
Lidocaine [DG:DG00196]
|
Melatonin
|
Sensitive (in vivo) |
Methoxsalen
|
Mexiletine [DG:DG00197]
|
Mianserin [DG:DG00951]
|
Mirtazapine
|
Modafinil
|
Naproxen [DG:DG00455]
|
Naratriptan [DG:DG00837]
|
Nicotine
|
 D03365 Nicotine (USP)
|
|
Norfloxacin [DG:DG00620]
|
Olanzapine [DG:DG00898]
|
Ondansetron [DG:DG00060]
|
Palonosetron [DG:DG00064]
|
Paracetamol
|
Phenacetin
|
Pimozide
|
Pirfenidone
|
Propafenone [DG:DG00200]
|
Propranolol [DG:DG00305]
|
Ramelteon
|
Sensitive (in vivo) |
Ramosetron [DG:DG01239]
|
Riluzole
|
Ropinirole [DG:DG00862]
|
Ropivacaine [DG:DG00806]
|
Tacrine
|
Sensitive (in vivo) |
Tamoxifen [DG:DG00734]
|
Theophylline
|
Narrow therapeutic range (in vivo) |
Terbinafine [DG:DG00375]
|
Tizanidine
|
Sensitive (in vivo) / Narrow therapeutic range (in vivo) |
Sarpogrelate
|
Stiripentol
|
Verapamil [DG:DG00329]
|
Warfarin [DG:DG00149]
|
Zileuton
|
Zolmitriptan
|
Zolpidem [DG:DG00922]
|
CYP1B1 [HSA:1545]
|
CYP2A6 [HSA:1548]
|
Letrozole
|
Methoxsalen
|
Nabumetone
|
Nicotine
|
D03365 Nicotine (USP)
|
|
Pilocarpine [DG:DG00992]
|
Rivaroxaban
|
CYP2B6 [HSA:1555]
|
CYP2C8 [HSA:1558]
|
CYP2C9 [HSA:1559]
|
CYP2C18 [HSA:1562]
|
CYP2C19 [HSA:1557]
|
CYP2D6 [HSA:1565]
|
CYP2J2 [HSA:1573]
|
CYP3A4 [HSA:1576]
|
CYP3A5 [HSA:1577]
|
CYP3A7 [HSA:1551]
|
CYP3A [HSA:1576 1577 1551]
|
CYP4B1 [HSA:1580]
|
|
|
Transporter inhibitors
|
|
|
Transporter inducers
|
|
|
Transporter substrates
|
Drug interactions with metabolizing enzymes and transporters